Nu Skin eyes deal with genomics firm to strengthen anti-aging platform

- Last updated on GMT

Related tags: Genetics

Nu Skin has issued a letter of intent to acquire LifeGen Technologies for over $11m in a bid to strengthen its ageLoc anti-aging platform.

Nu Skin began its scientific collaboration with the Wisconsin-based genomics company two years ago with LifeGen's proprietary genetic science supporting its anti-aging products, including the company's most recent introduction of the ageLoc R2 nutritional supplement.

"Our acquisition of LifeGen will further solidify the competitive advantage Nu Skin enjoys with our ageLoc anti-aging platform with exclusive access to LifeGen's breakthrough work on genetic sources of aging,"​ said CEO, Truman Hunt.

"The acquisition also makes financial sense as we will no longer incur royalty obligations on products developed with LifeGen's assistance. Overall, we believe that this acquisition of LifeGen will enhance our pipeline of next-generation anti-aging products for many years to come, allowing us to provide a steady stream of innovative anti-aging solutions aimed at helping people live younger, longer."

Related topics: Business & Financial

Related news

Follow us

Products

View more

Webinars